ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Merck Announces Positive Topline Results from Investigational 15-valent Pneumococcal Conjugate Vaccine
May 24, 2021Merck has announced that V114, the company’s investigational 15-valent pneumococcal conjugate vaccine, met its primary immunogenicity and safety endpoints in two trials of the V114 Phase 3 pediatric clinical program. -
FDA accepts priority review of Merck’s pneumococcal vaccine
January 14, 2021The US Food and Drug Administration (FDA) has accepted priority review of the Biologics License Application (BLA) of Merck’s investigational 15-valent pneumococcal conjugate vaccine candidate, V114, for preventing invasive pneumococcal disease in adults.
Pharma Sources Insight January 2025
